<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:dc="http://purl.org/dc/elements/1.1/">
  <channel>
    <title>SeekingAlpha.com: SA Currents</title>
    <link>http://seekingalpha.com/currents/all</link>
    <description>SA Currents RSS Syndication from SeekingAlpha.com</description>
    <author>
      <name>SeekingAlpha.com</name>
    </author>


      <item>
        <title><![CDATA[Shares of Sonic ([[SONC]] +1.8%) skate higher on the back of a Morgan Stanley upgrade to Equalweight from Underweight.]]></title>
        <link>http://seekingalpha.com/currents/post/1094392?source=feed</link>
        <guid isPermaLink="false">1094392</guid>
        <content>
          <![CDATA[ Shares of Sonic ([[SONC]] +1.8%) skate higher on the back of a Morgan Stanley upgrade to Equalweight from Underweight. <a href="http://seekingalpha.com/currents/post/1094392?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:19:27 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Shares of Sonic (<a href='http://seekingalpha.com/symbol/sonc' title='Sonic Corp.'>SONC</a> <font color='green'>+1.8%</font>) skate higher on the back of a <a href="http://www.streetinsider.com/Upgrades/Morgan+Stanley+Upgrades+Sonic+%28SONC%29+to+Equalweight/8429800.html" target="_blank">Morgan Stanley upgrade</a> to Equalweight from Underweight. <a href="http://seekingalpha.com/currents/post/1094392?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Raptor Pharmaceutical ([[RPTP]] +1.1%) says its Procysbi delayed-release capsules for the treatment of nephropathic cystinosis are now available in the U.S. for shipment. Nephropathic cystinosis is a rare, life-threatening metabolic lysosomal storage disorder that causes toxic accumulation of cystine in all cells, tissues, and organs in the body.]]></title>
        <link>http://seekingalpha.com/currents/post/1094382?source=feed</link>
        <guid isPermaLink="false">1094382</guid>
        <content>
          <![CDATA[ Raptor Pharmaceutical ([[RPTP]] +1.1%) says its Procysbi delayed-release capsules for the treatment of nephropathic cystinosis are now available in the U.S. for shipment. Nephropathic cystinosis is a rare, life-threatening metabolic lysosomal storage disorder that causes toxic accumulation of cystine in all cells, tissues, and organs in the body. <a href="http://seekingalpha.com/currents/post/1094382?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:17:43 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Raptor Pharmaceutical (<a href='http://seekingalpha.com/symbol/rptp' title='Raptor Pharmaceuticals Corp.'>RPTP</a> <font color="green">+1.1%</font>) says its Procysbi delayed-release capsules for the treatment of nephropathic cystinosis <a href="http://seekingalpha.com/news-article/6864592-raptor-s-procysbi-tm-now-commercially-available-in-the-u-s-for-nephropathic-cystinosis-patients" target="_blank">are now available</a> in the U.S. for shipment. Nephropathic cystinosis is a rare, life-threatening metabolic lysosomal storage disorder that causes toxic accumulation of cystine in all cells, tissues, and organs in the body. <a href="http://seekingalpha.com/currents/post/1094382?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Bond prices ([[TLT]] -0.7%) slip following the more upbeat assessment of the economy from the FOMC. Higher growth and lower unemployment projections spell maybe a quicker schedule for tapering and eventual tightening, but materially lower inflation expectations say the opposite. Stocks give up a bit of ground as well, the S&P 500 ([[SPY]] -0.3%). The dollar ([[UUP]] +0.3%) pops higher across the board.]]></title>
        <link>http://seekingalpha.com/currents/post/1094372?source=feed</link>
        <guid isPermaLink="false">1094372</guid>
        <content>
          <![CDATA[ Bond prices ([[TLT]] -0.7%) slip following the more upbeat assessment of the economy from the FOMC. Higher growth and lower unemployment projections spell maybe a quicker schedule for tapering and eventual tightening, but materially lower inflation expectations say the opposite. Stocks give up a bit of ground as well, the S&P 500 ([[SPY]] -0.3%). The dollar ([[UUP]] +0.3%) pops higher across the board. <a href="http://seekingalpha.com/currents/post/1094372?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 1 comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:13:47 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Bond prices (<a href='http://seekingalpha.com/symbol/tlt' title='iShares Barclays 20+ Year Treasury Bond ETF'>TLT</a> <font color='red'>-0.7%</font>) slip following the <a href="http://seekingalpha.com/currents/post/1094332" target="_blank">more upbeat</a> assessment of the economy from the FOMC. Higher growth and lower unemployment <a href="http://seekingalpha.com/currents/post/1094362" target="_blank">projections</a> spell maybe a quicker schedule for tapering and eventual tightening, but materially lower inflation expectations say the opposite. Stocks give up a bit of ground as well, the S&amp;P 500 (<a href='http://seekingalpha.com/symbol/spy' title='SPDR S&P 500 Trust ETF'>SPY</a> <font color='red'>-0.3%</font>). The dollar (<a href='http://seekingalpha.com/symbol/uup' title='PowerShares DB USD Bull ETF'>UUP</a> <font color='green'>+0.3%</font>) pops higher across the board. <a href="http://seekingalpha.com/currents/post/1094372?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 1 comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[FOMC Economic Projections: 2013 GDP growth estimate is cut a hair to 2.3-2.6% from 2.3-2.8%, but is boosted in 2014 to 3-3.5% from 2.9-3.4%. The unemployment rate forecast for 2013 is trimmed to 7.2-7.3% from 7.3-7.5% and in 2014 to 6.5-6.8% from 6.7-7%. Core CPI expectations are cut to 1.2-1.3% this year from 1.5-1.6% and in 2014 to 1.5-1.8% from 1.7-2%. 14 out of 19 FOMC members see rate hikes beginning in 2015 (4 see hikes before then).]]></title>
        <link>http://seekingalpha.com/currents/post/1094362?source=feed</link>
        <guid isPermaLink="false">1094362</guid>
        <content>
          <![CDATA[ FOMC Economic Projections: 2013 GDP growth estimate is cut a hair to 2.3-2.6% from 2.3-2.8%, but is boosted in 2014 to 3-3.5% from 2.9-3.4%. The unemployment rate forecast for 2013 is trimmed to 7.2-7.3% from 7.3-7.5% and in 2014 to 6.5-6.8% from 6.7-7%. Core CPI expectations are cut to 1.2-1.3% this year from 1.5-1.6% and in 2014 to 1.5-1.8% from 1.7-2%. 14 out of 19 FOMC members see rate hikes beginning in 2015 (4 see hikes before then). <a href="http://seekingalpha.com/currents/post/1094362?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:06:39 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ <strong><a href="http://www.federalreserve.gov/monetarypolicy/files/fomcprojtabl20130619.pdf" target="_blank">FOMC Economic Projections:</a></strong> 2013 GDP growth estimate is cut a hair to 2.3-2.6% from 2.3-2.8%, but is boosted in 2014 to 3-3.5% from 2.9-3.4%. The unemployment rate forecast for 2013 is trimmed to 7.2-7.3% from 7.3-7.5% and in 2014 to 6.5-6.8% from 6.7-7%. Core CPI expectations are cut to 1.2-1.3% this year from 1.5-1.6% and in 2014 to 1.5-1.8% from 1.7-2%. 14 out of 19 FOMC members see rate hikes beginning in 2015 (4 see hikes before then). <a href="http://seekingalpha.com/currents/post/1094362?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Lazard raises its FY14 EPS estimate for Chicago Bridge & Iron ([[CBI]] +0.7%) to $5.33 from $5. Analyst Will Gabrielski is now looking for the shares to hit $75, representing a near 23% upside from Tuesday's close.]]></title>
        <link>http://seekingalpha.com/currents/post/1094352?source=feed</link>
        <guid isPermaLink="false">1094352</guid>
        <content>
          <![CDATA[ Lazard raises its FY14 EPS estimate for Chicago Bridge & Iron ([[CBI]] +0.7%) to $5.33 from $5. Analyst Will Gabrielski is now looking for the shares to hit $75, representing a near 23% upside from Tuesday's close. <a href="http://seekingalpha.com/currents/post/1094352?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:06:25 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Lazard <a href="http://www.streetinsider.com/Analyst+Comments/Lazard+Raises+PT+on+Chicago+Bridge+%26+Iron+%28CBI%29+to+%2475/8430258.html" target="_blank">raises its FY14 EPS estimate</a> for Chicago Bridge &amp; Iron (<a href='http://seekingalpha.com/symbol/cbi' title='Chicago Bridge & Iron Company'>CBI</a> <font color='green'>+0.7%</font>) to $5.33 from $5. Analyst Will Gabrielski is now looking for the shares to hit $75, representing a near <font color="green">23%</font> upside from Tuesday's close. <a href="http://seekingalpha.com/currents/post/1094352?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Analysts weren't surprised by the when-issued trading in Australia of the new companies emerging from the split of News Corp. ([[NWS]], [[NWSA]]). In their debut in Sydney, 21st Century Fox (Fox movie, pay TV and free TV busines, Sky Deutschland, Sky Italia, part of BskyB ) rose over 5% while the new News Corp. (Wall Street Journal, The Sun, Barron's, Australian media assets) dropped 3%.]]></title>
        <link>http://seekingalpha.com/currents/post/1094342?source=feed</link>
        <guid isPermaLink="false">1094342</guid>
        <content>
          <![CDATA[ Analysts weren't surprised by the when-issued trading in Australia of the new companies emerging from the split of News Corp. ([[NWS]], [[NWSA]]). In their debut in Sydney, 21st Century Fox (Fox movie, pay TV and free TV busines, Sky Deutschland, Sky Italia, part of BskyB ) rose over 5% while the new News Corp. (Wall Street Journal, The Sun, Barron's, Australian media assets) dropped 3%. <a href="http://seekingalpha.com/currents/post/1094342?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:03:24 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Analysts <a href="http://www.hollywoodreporter.com/news/new-news-corp-stock-drops-571690" target="_blank">weren't surprised</a> by the <a href="http://seekingalpha.com/currents/post/1092692" target="_blank">when-issued trading</a> in Australia of the new companies emerging from the split of News Corp. (<a href='http://seekingalpha.com/symbol/nws' title='News Corporation'>NWS</a>, <a href='http://seekingalpha.com/symbol/nwsa' title='News Corporation'>NWSA</a>). In their debut in Sydney, 21st Century Fox (Fox movie, pay TV and free TV busines, Sky Deutschland, Sky Italia, part of BskyB ) rose over 5% while the new News Corp. (Wall Street Journal, The Sun, Barron's, Australian media assets) dropped 3%. <a href="http://seekingalpha.com/currents/post/1094342?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[FOMC Announcement: No changes to the $85B per month in asset purchases and the committee stands ready to increase or decrease the level as necessary. Downside risks to the economy and the labor market have diminished since the fall.]]></title>
        <link>http://seekingalpha.com/currents/post/1094332?source=feed</link>
        <guid isPermaLink="false">1094332</guid>
        <content>
          <![CDATA[ FOMC Announcement: No changes to the $85B per month in asset purchases and the committee stands ready to increase or decrease the level as necessary. Downside risks to the economy and the labor market have diminished since the fall. <a href="http://seekingalpha.com/currents/post/1094332?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 3 comments!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:01:22 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ <strong><a href="http://www.federalreserve.gov/monetarypolicy/fomccalendars.htm" target="_blank">FOMC Announcement:</a></strong>&nbsp;No changes to the $85B per month in asset purchases and the committee stands ready to increase or decrease the level as necessary. Downside risks to the economy and the labor market <strong>have diminished</strong> since the fall. <a href="http://seekingalpha.com/currents/post/1094332?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 3 comments!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Ahead of Micron's ([[MU]] +0.4%) afternoon FQ3 report, Charles Kau, the chairman of Micron's Inotera JV, predicts the current DRAM shortage will last through 2015, thanks to controlled expansion and surging mobile DRAM usage. Kau expects DRAM demand to outstrip supply by 3% in 2013, 5%, in 2014, and 7% in 2015. Those numbers back up recent comments from Credit Suisse, which declared the DRAM industry is seeing structural improvements following a wave of consolidation around Micron, Samsung (SSNLF.PK), and SK Hynix. Analyst commentary on Micron has been very positive going into earnings, but a lot of good news has been priced in.]]></title>
        <link>http://seekingalpha.com/currents/post/1094322?source=feed</link>
        <guid isPermaLink="false">1094322</guid>
        <content>
          <![CDATA[ Ahead of Micron's ([[MU]] +0.4%) afternoon FQ3 report, Charles Kau, the chairman of Micron's Inotera JV, predicts the current DRAM shortage will last through 2015, thanks to controlled expansion and surging mobile DRAM usage. Kau expects DRAM demand to outstrip supply by 3% in 2013, 5%, in 2014, and 7% in 2015. Those numbers back up recent comments from Credit Suisse, which declared the DRAM industry is seeing structural improvements following a wave of consolidation around Micron, Samsung (SSNLF.PK), and SK Hynix. Analyst commentary on Micron has been very positive going into earnings, but a lot of good news has been priced in. <a href="http://seekingalpha.com/currents/post/1094322?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 14:01:10 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Ahead of Micron's (<a href='http://seekingalpha.com/symbol/mu' title='Micron Technology Inc.'>MU</a> <font color="green">+0.4%</font>) afternoon FQ3 report, Charles Kau, the chairman of Micron's Inotera JV, predicts the current DRAM shortage will <a target="_blank" href="http://www.digitimes.com/news/a20130619PD209.html">last through 2015</a>, thanks to controlled expansion and surging <a target="_blank" href="http://seekingalpha.com/currents/post/734991">mobile DRAM usage</a>. Kau expects DRAM demand to outstrip supply by 3% in 2013, 5%, in 2014, and 7% in 2015. Those numbers back up <a target="_blank" href="https://twitter.com/thenotablecalls/status/346611221178507264">recent comments</a> from Credit Suisse, which declared the DRAM industry is seeing structural improvements following a wave of consolidation around Micron, Samsung (<a href='http://seekingalpha.com/symbol/ssnlf.pk' title='Samsung Elect Ltd&#40;F&#41;'>SSNLF.PK</a>), and SK Hynix. Analyst commentary on Micron has been <a target="_blank" href="http://seekingalpha.com/currents/post/1088582">very positive</a> going into earnings, but a lot of good news has been <a target="_blank" href="https://www.google.com/finance?chdnp=1&amp;chdd=1&amp;chds=1&amp;chdv=1&amp;chvs=maximized&amp;chdeh=0&amp;chfdeh=0&amp;chdet=1371240000000&amp;chddm=44491&amp;chls=IntervalBasedLine&amp;q=NASDAQ:MU&amp;ntsp=0&amp;ei=WvHBUYHzLa-ziAKbyQE">priced in</a>. <a href="http://seekingalpha.com/currents/post/1094322?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Inergy ([[NRGY]] -37.5%) completes its distribution to unitholders of the ~56.4M  common units it previously held in Inergy Midstream ([[NRGM]] -1.3%), marking the first step in Crestwood Midstream's ([[CMLP]] +1%) takeover of NRGY, which is expected to close by Q3. Raymond James calls the move a "structural cleanup" ahead of CMLP's takeover.]]></title>
        <link>http://seekingalpha.com/currents/post/1094312?source=feed</link>
        <guid isPermaLink="false">1094312</guid>
        <content>
          <![CDATA[ Inergy ([[NRGY]] -37.5%) completes its distribution to unitholders of the ~56.4M  common units it previously held in Inergy Midstream ([[NRGM]] -1.3%), marking the first step in Crestwood Midstream's ([[CMLP]] +1%) takeover of NRGY, which is expected to close by Q3. Raymond James calls the move a "structural cleanup" ahead of CMLP's takeover. <a href="http://seekingalpha.com/currents/post/1094312?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:59:21 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Inergy (<a href='http://seekingalpha.com/symbol/nrgy' title='Inergy, L.P.'>NRGY</a> <font color="red">-37.5%</font>) <a href="http://seekingalpha.com/news-article/6865072-inergy-completes-distribution-of-inergy-midstream-units-to-unitholders" target="_blank">completes its distribution</a> to unitholders of the ~56.4M  common units it previously held in Inergy Midstream (<a href='http://seekingalpha.com/symbol/nrgm' title='Inergy Midstream LP'>NRGM</a> <font color="red">-1.3%</font>), marking the first step in Crestwood Midstream's (<a href='http://seekingalpha.com/symbol/cmlp' title='Crestwood Midstream Partners LP'>CMLP</a> <font color="green">+1%</font>) takeover of NRGY, which is expected to close by Q3. Raymond James calls the move a "<a href="http://finance.yahoo.com/news/inergy-distributes-inergy-midstream-units-155852420.html" target="_blank">structural cleanup</a>" ahead of CMLP's takeover. <a href="http://seekingalpha.com/currents/post/1094312?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Neurocrine Biosciences ([[NBIX]] +2.7%) moves up today after being initiated by Oppenheimer with an Outperform rating. The firm says that its sees blockbuster potential for elagolix, with Phase 3 endometriosis results expected in H114 and Phase 2 results in H214. A secondary asset, NBI-98854, a Vesicular Mono-Amine Transporter 2 compound for treating tardive dyskinesia, is risky, but only modest value is baked in.]]></title>
        <link>http://seekingalpha.com/currents/post/1094302?source=feed</link>
        <guid isPermaLink="false">1094302</guid>
        <content>
          <![CDATA[ Neurocrine Biosciences ([[NBIX]] +2.7%) moves up today after being initiated by Oppenheimer with an Outperform rating. The firm says that its sees blockbuster potential for elagolix, with Phase 3 endometriosis results expected in H114 and Phase 2 results in H214. A secondary asset, NBI-98854, a Vesicular Mono-Amine Transporter 2 compound for treating tardive dyskinesia, is risky, but only modest value is baked in. <a href="http://seekingalpha.com/currents/post/1094302?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:53:08 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Neurocrine Biosciences (<a href='http://seekingalpha.com/symbol/nbix' title='Neurocrine Biosciences, Inc.'>NBIX</a> <font color="green">+2.7%</font>) moves up today after <a href="http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3686929/update-oppenheimer-initiates-coverage-on-neurocrine-bios" target="_blank">being initiated</a> by Oppenheimer with an Outperform rating. The firm says that its sees blockbuster potential for elagolix, with Phase 3 endometriosis results expected in H114 and Phase 2 results in H214. A secondary asset, NBI-98854, a Vesicular Mono-Amine Transporter 2 compound for treating tardive dyskinesia, is risky, but only modest value is baked in. <a href="http://seekingalpha.com/currents/post/1094302?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Though high-end Lumia models such as the 920, 925, and (expected) EOS get most of the ink, the low-end 520 could be the biggest seller in Nokia's ([[NOK]] -0.3%) Windows Phone lineup. Google Trends data points to surging interest in the 520, which features a 4" display, lacks 4G support, and is dirt cheap - Wal-Mart sells the 521, a variant working on T-Mobile's network, for an unsubsidized $130 .... if it's in stock. Also, the 520 is now #2 in GSM Arena's daily interest rankings, behind only the Galaxy S4; no other Nokia phone is in the top-10.]]></title>
        <link>http://seekingalpha.com/currents/post/1094292?source=feed</link>
        <guid isPermaLink="false">1094292</guid>
        <content>
          <![CDATA[ Though high-end Lumia models such as the 920, 925, and (expected) EOS get most of the ink, the low-end 520 could be the biggest seller in Nokia's ([[NOK]] -0.3%) Windows Phone lineup. Google Trends data points to surging interest in the 520, which features a 4" display, lacks 4G support, and is dirt cheap - Wal-Mart sells the 521, a variant working on T-Mobile's network, for an unsubsidized $130 .... if it's in stock. Also, the 520 is now #2 in GSM Arena's daily interest rankings, behind only the Galaxy S4; no other Nokia phone is in the top-10. <a href="http://seekingalpha.com/currents/post/1094292?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 8 comments!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:36:05 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Though high-end Lumia models such as the 920, 925, and (<a href="http://seekingalpha.com/currents/post/1069041" target="_blank">expected</a>) EOS get most of the ink, the low-end 520 <a href="http://www.streetinsider.com/Insiders+Blog/Nokia+%28NOK%29+Lumia+520+Quickly+Becoming+Go-To+Windows+Phone+Device/8431208.html" target="_blank">could be the biggest seller</a> in Nokia's (<a href='http://seekingalpha.com/symbol/nok' title='Nokia Corporation'>NOK</a> <font color='red'>-0.3%</font>) Windows Phone lineup. <a href="http://wmpoweruser.com/nokia-lumia-520-interest-still-increasing/" target="_blank">Google Trends data</a> points to surging interest in the 520, which <a href="http://seekingalpha.com/currents/post/848831" target="_blank">features a 4" display</a>, lacks 4G support, and is dirt cheap - <a href="http://www.walmart.com/ip/Nokia-Lumia-521-4G-Smartphone/24099994?affillinktype=10&amp;dest=9999999997&amp;sourceid=34830337892557416891&amp;veh=aff&amp;wmlspartner=lw9MynSeamY" target="_blank">Wal-Mart sells</a> the 521, a variant working on T-Mobile's network, for an unsubsidized $130 .... <a href="http://www.wpcentral.com/walmart-has-nokia-lumia-521-stock-select-stores" target="_blank">if it's in stock</a>. Also, the 520 is now #2 in GSM Arena's <a href="http://www.gsmarena.com/" target="_blank">daily interest rankings</a>, behind only the Galaxy S4; no other Nokia phone is in the top-10. <a href="http://seekingalpha.com/currents/post/1094292?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 8 comments!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Nektar Therapeutics ([[NKTR]] +8.8%) rises after saying NKTR-181 (basically an opioid which doesn't act like an opioid in terms of euphoric effects) "rated similar to placebo in 'drug liking' and 'feeling high' scores" compared to oxycodone. The drug's slow rate of entry into the brain is intended to reduce the euphoria that is often cited as a contributor to opioid analgesic addiction. (PR)]]></title>
        <link>http://seekingalpha.com/currents/post/1094282?source=feed</link>
        <guid isPermaLink="false">1094282</guid>
        <content>
          <![CDATA[ Nektar Therapeutics ([[NKTR]] +8.8%) rises after saying NKTR-181 (basically an opioid which doesn't act like an opioid in terms of euphoric effects) "rated similar to placebo in 'drug liking' and 'feeling high' scores" compared to oxycodone. The drug's slow rate of entry into the brain is intended to reduce the euphoria that is often cited as a contributor to opioid analgesic addiction. (PR) <a href="http://seekingalpha.com/currents/post/1094282?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:35:18 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Nektar Therapeutics (<a href='http://seekingalpha.com/symbol/nktr' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+8.8%</font>) rises after saying NKTR-181 (basically an opioid which doesn't act like an opioid in terms of euphoric effects) "rated similar to placebo in 'drug liking' and 'feeling high' scores" compared to oxycodone. The drug's slow rate of entry into the brain is intended to reduce the euphoria that is often cited as a contributor to opioid analgesic addiction. (<a href="http://seekingalpha.com/news-article/6866742-nektar-therapeutics-presents-positive-data-from-human-abuse-liability-study-for-nktr-181-a-first-in-class-investigational-opioid-to-treat-chronic-pain-at-2013-annual-meeting-of-the-college-on-problems-of-drug-dependence" target="_blank">PR</a>) <a href="http://seekingalpha.com/currents/post/1094282?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Procter & Gamble ([[PG]] +0.2%) announces a new licensing agreement with Alexander McQueen. Under the terms of the deal, P&G will be able to immediately market fragrances under the Alexander McQueen brand name. What to watch: During last week's presentation (slides) at the Deutsche Bank Global Consumer Conference, execs said the company will increase its focus on making "value and performance" claims on its large stable of brands. On that note, a fragrance fit for a future queen could be an upcoming tag line.]]></title>
        <link>http://seekingalpha.com/currents/post/1094272?source=feed</link>
        <guid isPermaLink="false">1094272</guid>
        <content>
          <![CDATA[ Procter & Gamble ([[PG]] +0.2%) announces a new licensing agreement with Alexander McQueen. Under the terms of the deal, P&G will be able to immediately market fragrances under the Alexander McQueen brand name. What to watch: During last week's presentation (slides) at the Deutsche Bank Global Consumer Conference, execs said the company will increase its focus on making "value and performance" claims on its large stable of brands. On that note, a fragrance fit for a future queen could be an upcoming tag line. <a href="http://seekingalpha.com/currents/post/1094272?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:33:36 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Procter &amp; Gamble (<a href='http://seekingalpha.com/symbol/pg' title='Procter & Gamble Co.'>PG</a> <font color='green'>+0.2%</font>) <a href="http://seekingalpha.com/news-article/6870442-procter-gamble-and-alexander-mcqueen-announce-fragrance-license-agreement" target="_blank">announces</a> a new licensing agreement with Alexander McQueen. Under the terms of the deal, P&amp;G will be able to immediately market fragrances under the Alexander McQueen brand name. What to watch: During last week's presentation (<a href="http://www.pginvestor.com/phoenix.zhtml?c=104574&amp;p=irol-presentations" target="_blank">slides</a>) at the Deutsche Bank Global Consumer Conference, execs said the company will increase its focus on making "value and performance" claims on its large stable of brands. On that note, a fragrance <a href="http://www.refinery29.com/2013/06/48714/alexander-mcqueen-fragrance-deal" target="_blank">fit for a future queen</a> could be an upcoming tag line. <a href="http://seekingalpha.com/currents/post/1094272?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Shares of Oxygen Biotherapeutics ([[OXBT]] +10.9%) extend yesterday's 2.6% closing gain after the company announced on yesterday that it's completed FDA requested studies on its Oxycyte, a treatment for traumatic brain injury and other brain conditions. The company says the results were positive overall, but it will continue to conduct more studies on the treatment.]]></title>
        <link>http://seekingalpha.com/currents/post/1094262?source=feed</link>
        <guid isPermaLink="false">1094262</guid>
        <content>
          <![CDATA[ Shares of Oxygen Biotherapeutics ([[OXBT]] +10.9%) extend yesterday's 2.6% closing gain after the company announced on yesterday that it's completed FDA requested studies on its Oxycyte, a treatment for traumatic brain injury and other brain conditions. The company says the results were positive overall, but it will continue to conduct more studies on the treatment. <a href="http://seekingalpha.com/currents/post/1094262?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:33:06 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Shares of Oxygen Biotherapeutics (<a href='http://seekingalpha.com/symbol/oxbt' title='Oxygen Biotherapeutics, Inc. '>OXBT</a> <font color="green">+10.9%</font>) extend yesterday's 2.6% closing gain after the company announced on yesterday that it's <a href="http://seekingalpha.com/news-article/6861882-oxygen-biotherapeutics-reports-successful-completion-of-fda-requested-immunocompetency-studies-on-oxycyte-r" target="_blank">completed FDA requested studies</a> on its Oxycyte, a treatment for traumatic brain injury and other brain conditions. The company says the results were positive overall, but it will continue to conduct more studies on the treatment. <a href="http://seekingalpha.com/currents/post/1094262?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[An AMA designation might have no legal standing but new legislation aimed at Medicare coverage for weight-loss drugs could change that. Sens. Tom Carper and Lisa Murkowski and Reps. Bill Cassidy, M.D. and Ron Kind have introduced The Treat and Reduce Obesity Act which would, among other things , "allow Medicare to cover additional obesity treatments (beyond surgery) such as prescription drugs for chronic weight management." Leerink's Marko Kozul says the news "could provide further upside to current estimates" for Arena ([[ARNA]] +2.7%), Orexigen ([[OREX]] +0.5%), and Vivus ([[VVUS]] +7.7%).]]></title>
        <link>http://seekingalpha.com/currents/post/1094252?source=feed</link>
        <guid isPermaLink="false">1094252</guid>
        <content>
          <![CDATA[ An AMA designation might have no legal standing but new legislation aimed at Medicare coverage for weight-loss drugs could change that. Sens. Tom Carper and Lisa Murkowski and Reps. Bill Cassidy, M.D. and Ron Kind have introduced The Treat and Reduce Obesity Act which would, among other things , "allow Medicare to cover additional obesity treatments (beyond surgery) such as prescription drugs for chronic weight management." Leerink's Marko Kozul says the news "could provide further upside to current estimates" for Arena ([[ARNA]] +2.7%), Orexigen ([[OREX]] +0.5%), and Vivus ([[VVUS]] +7.7%). <a href="http://seekingalpha.com/currents/post/1094252?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:26:07 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ An AMA designation might have <a href="http://seekingalpha.com/currents/post/1092712" target="_blank">no legal standing</a> but <a href="http://www.benzinga.com/news/13/06/3690006/senators-carper-murkowski-representatives-cassidy-kind-introduce-bill-to-help-red" target="_blank">new legislation</a> aimed at Medicare coverage for weight-loss drugs could change that. Sens. Tom Carper and Lisa Murkowski and Reps. Bill Cassidy, M.D. and Ron Kind have introduced <i>The Treat and Reduce Obesity Act </i>which would, among other things , "allow Medicare to cover additional obesity treatments (beyond surgery) such as prescription drugs for chronic weight management." Leerink's Marko Kozul says the news "could <a href="http://www.streetinsider.com/Analyst+Comments/Bill+for+Medicare+Coverage%2C+AMA+Designation+Positive+for+Obesity+Drug+Makers+%28ARNA%29+%28VVUS%29+%28OREX%29+-+Leerink+Swann/8431547.html" target="_blank">provide further upside</a> to current estimates" for Arena (<a href='http://seekingalpha.com/symbol/arna' title='Arena Pharmaceuticals, Inc.'>ARNA</a> <font color='green'>+2.7%</font>), Orexigen (<a href='http://seekingalpha.com/symbol/orex' title='Orexigen Therapeutics, Inc.'>OREX</a> <font color='green'>+0.5%</font>), and Vivus (<a href='http://seekingalpha.com/symbol/vvus' title='Vivus, Inc.'>VVUS</a> <font color='green'>+7.7%</font>). <a href="http://seekingalpha.com/currents/post/1094252?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Shares of clinical stage biopharmaceutical company Intercept Pharmaceuticals (ICPT) are now up over 13% after pricing its public offering of 1.73M shares at $33.01 per share in line with yesterday's close.]]></title>
        <link>http://seekingalpha.com/currents/post/1094242?source=feed</link>
        <guid isPermaLink="false">1094242</guid>
        <content>
          <![CDATA[ Shares of clinical stage biopharmaceutical company Intercept Pharmaceuticals (ICPT) are now up over 13% after pricing its public offering of 1.73M shares at $33.01 per share in line with yesterday's close. <a href="http://seekingalpha.com/currents/post/1094242?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:16:48 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Shares of clinical stage biopharmaceutical company Intercept Pharmaceuticals (<a href='http://seekingalpha.com/symbol/icpt' title='Intercept Pharmaceuticals'>ICPT</a>) are now up over <font color="green">13%</font> after pricing its <a href="http://seekingalpha.com/market_currents/post/1092982" target="_blank">public offering</a> of 1.73M shares at $33.01 per share in line with yesterday's close. <a href="http://seekingalpha.com/currents/post/1094242?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[While Amazon plots a big expansion of its U.S. grocery delivery business, eBay's (EBAY) Indian site has begun selling food/grocery items through a section called eBay Daily. 1,600 products, generally packaged goods, are available for sale. eBay's move comes a couple months after it led a $50M funding round for local e-commerce marketplace Snapdeal, and a year after it announced plans to invest heavily in the Indian market, where e-commerce penetration is still low and Amazon (AMZN), which just launched an Indian marketplace site, has been slowed by foreign investment rules.]]></title>
        <link>http://seekingalpha.com/currents/post/1094232?source=feed</link>
        <guid isPermaLink="false">1094232</guid>
        <content>
          <![CDATA[ While Amazon plots a big expansion of its U.S. grocery delivery business, eBay's (EBAY) Indian site has begun selling food/grocery items through a section called eBay Daily. 1,600 products, generally packaged goods, are available for sale. eBay's move comes a couple months after it led a $50M funding round for local e-commerce marketplace Snapdeal, and a year after it announced plans to invest heavily in the Indian market, where e-commerce penetration is still low and Amazon (AMZN), which just launched an Indian marketplace site, has been slowed by foreign investment rules. <a href="http://seekingalpha.com/currents/post/1094232?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 2 comments!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:15:42 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ While Amazon <a target="_blank" href="http://seekingalpha.com/currents/post/1063841">plots a big expansion</a> of its U.S. grocery delivery business, eBay's (<a href='http://seekingalpha.com/symbol/ebay' title='eBay Inc.'>EBAY</a>) <a target="_blank" href="http://www.ebay.in/hp?_feedexp=0">Indian site</a> has begun <a target="_blank" href="http://www.techinasia.com/ebay-homeshop18-add-food-groceries-india/">selling food/grocery items</a> through a section called eBay Daily. 1,600 products, generally packaged goods, are available for sale. eBay's move comes a couple months after it <a target="_blank" href="http://seekingalpha.com/currents/post/918411">led a $50M funding round</a> for local e-commerce marketplace Snapdeal, and a year after it announced plans to <a target="_blank" href="http://seekingalpha.com/currents/post/223451">invest heavily</a> in the Indian market, where e-commerce penetration is still low and Amazon (<a href='http://seekingalpha.com/symbol/amzn' title='Amazon.com, Inc.'>AMZN</a>), which <a target="_blank" href="http://seekingalpha.com/currents/post/1064891">just launched</a> an Indian marketplace site, has been slowed by foreign investment rules. <a href="http://seekingalpha.com/currents/post/1094232?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 2 comments!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[ESB Financial Corporation (ESBF) declares $0.10/share quarterly dividend, in line with previous. Forward yield 3.29%. For shareholders of record June 28. Payable July 25. Ex-div date June 26. (PR)]]></title>
        <link>http://seekingalpha.com/currents/post/1094222?source=feed</link>
        <guid isPermaLink="false">1094222</guid>
        <content>
          <![CDATA[ ESB Financial Corporation (ESBF) declares $0.10/share quarterly dividend, in line with previous. Forward yield 3.29%. For shareholders of record June 28. Payable July 25. Ex-div date June 26. (PR) <a href="http://seekingalpha.com/currents/post/1094222?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:09:51 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ <b>ESB Financial Corporation (<a href='http://seekingalpha.com/symbol/esbf' title='ESB Financial Corporation'>ESBF</a>)</b> declares $0.10/share quarterly dividend, in line with previous. Forward yield 3.29%. For shareholders of record June 28. Payable July 25. Ex-div date June 26. (<a href="http://seekingalpha.com/news-article/6870792-esb-financial-corporation-announces-cash-dividend" target="_blank">PR</a>) <a href="http://seekingalpha.com/currents/post/1094222?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[MediciNova ([[MNOV]] +29.6%) soars after the company says its glial attenuator MN-166 may reduce methamphetamine's neurotoxic inflammation and might also "attenuate other actions contributing to methamphetamine dependence." The company plans to initiate a Phase 2 trial "later this summer." (PR)]]></title>
        <link>http://seekingalpha.com/currents/post/1094212?source=feed</link>
        <guid isPermaLink="false">1094212</guid>
        <content>
          <![CDATA[ MediciNova ([[MNOV]] +29.6%) soars after the company says its glial attenuator MN-166 may reduce methamphetamine's neurotoxic inflammation and might also "attenuate other actions contributing to methamphetamine dependence." The company plans to initiate a Phase 2 trial "later this summer." (PR) <a href="http://seekingalpha.com/currents/post/1094212?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:07:17 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ MediciNova (<a href='http://seekingalpha.com/symbol/mnov' title='MediciNova, Inc.'>MNOV</a> <font color='green'>+29.6%</font>) soars after the company says its glial attenuator MN-166 may reduce methamphetamine's neurotoxic inflammation and might also "attenuate other actions contributing to methamphetamine dependence." The company plans to initiate a Phase 2 trial "later this summer." (<a href="http://seekingalpha.com/news-article/6862442-ucla-presents-data-on-medicinova-s-mn-166-in-methamphetamine-addiction-at-the-75th-annual-meeting-of-the-college-on-problems-of-drug-dependence" target="_blank">PR</a>) <a href="http://seekingalpha.com/currents/post/1094212?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[The mystery behind the ouster of Men's Wearhouse ([[MW]] -1.9%) founder George Zimmer lies behind the doors at the company where the exec had significant difficulty giving up control, according to Stifel Nicolaus. The investment firm backs its Buy rating on the retailer, noting current management including creator director Joseph Abboud are on the right track.]]></title>
        <link>http://seekingalpha.com/currents/post/1094202?source=feed</link>
        <guid isPermaLink="false">1094202</guid>
        <content>
          <![CDATA[ The mystery behind the ouster of Men's Wearhouse ([[MW]] -1.9%) founder George Zimmer lies behind the doors at the company where the exec had significant difficulty giving up control, according to Stifel Nicolaus. The investment firm backs its Buy rating on the retailer, noting current management including creator director Joseph Abboud are on the right track. <a href="http://seekingalpha.com/currents/post/1094202?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:06:41 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ The mystery behind the ouster of Men's Wearhouse (<a href='http://seekingalpha.com/symbol/mw' title='Men&#39;s Wearhouse Inc.'>MW</a> <font color='red'>-1.9%</font>) founder George Zimmer lies behind the doors at the company where the exec had significant difficulty giving up control, according to Stifel Nicolaus. The investment firm <a href="http://abcnews.go.com/Business/effectiveness-mens-wearhouse-george-zimmer-spokesperson-review-analyst/story?id=19436560#.UcHjgPk4T0s" target="_blank">backs</a> its Buy rating on the retailer, noting current management including creator director Joseph Abboud are on the right track. <a href="http://seekingalpha.com/currents/post/1094202?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[The First of Long Island Corporation (FLIC) declares $0.25/share quarterly dividend, in line with previous. Forward yield 3.05%. For shareholders of record July 5. Payable July 15. Ex-div date July 3. (PR)]]></title>
        <link>http://seekingalpha.com/currents/post/1094192?source=feed</link>
        <guid isPermaLink="false">1094192</guid>
        <content>
          <![CDATA[ The First of Long Island Corporation (FLIC) declares $0.25/share quarterly dividend, in line with previous. Forward yield 3.05%. For shareholders of record July 5. Payable July 15. Ex-div date July 3. (PR) <a href="http://seekingalpha.com/currents/post/1094192?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:06:06 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ <b>The First of Long Island Corporation (<a href='http://seekingalpha.com/symbol/flic' title='The First of Long Island Corporation'>FLIC</a>)</b> declares $0.25/share quarterly dividend, in line with previous. Forward yield 3.05%. For shareholders of record July 5. Payable July 15. Ex-div date July 3. (<a href="http://seekingalpha.com/news-article/6870612-the-first-of-long-island-corporation-announces-quarterly-cash-dividend-of-25-cents-per-share" target="_blank">PR</a>) <a href="http://seekingalpha.com/currents/post/1094192?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Bank of Commerce Holdings (BOCH) declares $0.03/share quarterly dividend, in line with previous. Forward yield 2.46%. For shareholders of record June 28. Payable July 12. Ex-div date June 26. (PR)]]></title>
        <link>http://seekingalpha.com/currents/post/1094182?source=feed</link>
        <guid isPermaLink="false">1094182</guid>
        <content>
          <![CDATA[ Bank of Commerce Holdings (BOCH) declares $0.03/share quarterly dividend, in line with previous. Forward yield 2.46%. For shareholders of record June 28. Payable July 12. Ex-div date June 26. (PR) <a href="http://seekingalpha.com/currents/post/1094182?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 13:01:32 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ <b>Bank of Commerce Holdings (<a href='http://seekingalpha.com/symbol/boch' title='Bank of Commerce Holdings &#40;CA&#41;'>BOCH</a>)</b> declares $0.03/share quarterly dividend, in line with previous. Forward yield 2.46%. For shareholders of record June 28. Payable July 12. Ex-div date June 26. (<a target="_blank" href="http://seekingalpha.com/news-article/6870502-bank-of-commerce-holdings-tm-announces-second-quarter-cash-dividend-of-0-03">PR</a>) <a href="http://seekingalpha.com/currents/post/1094182?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[The AMA officially endorses a policy to limit how caffeinated beverages are marketed to consumers under the age of 18 and calls for a temporary ban on youth marketing until more studies are completed. Shares of Monster Beverage ([[MNST]] -0.4%) are only off moderately with the risks of legislation on energy drink marketing already baked in.]]></title>
        <link>http://seekingalpha.com/currents/post/1094172?source=feed</link>
        <guid isPermaLink="false">1094172</guid>
        <content>
          <![CDATA[ The AMA officially endorses a policy to limit how caffeinated beverages are marketed to consumers under the age of 18 and calls for a temporary ban on youth marketing until more studies are completed. Shares of Monster Beverage ([[MNST]] -0.4%) are only off moderately with the risks of legislation on energy drink marketing already baked in. <a href="http://seekingalpha.com/currents/post/1094172?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 1 comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:59:18 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ The AMA officially <a target="_blank" href="http://www.bloomberg.com/news/2013-06-18/doctors-call-for-halt-to-energy-drink-ads-to-u-s-youths.html">endorses</a> a policy to limit how caffeinated beverages are marketed to consumers under the age of 18 and calls for a temporary ban on youth marketing until more studies are completed. Shares of Monster Beverage (<a href='http://seekingalpha.com/symbol/mnst' title='Monster Beverage Corp.'>MNST</a> <font color="red">-0.4%</font>) are only off moderately with the risks of legislation on energy drink marketing already baked in. <a href="http://seekingalpha.com/currents/post/1094172?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> 1 comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Sonoco Products ([[SON]] -1.4%) is downgraded to Neutral from Outperform with an amended price objective of $37 by Robert W. Baird, which says that while SON management is pursuing the right strategy of portfolio optimization and a bias toward share buybacks, YTD share outperformance has left the risk-reward ratio less compelling.]]></title>
        <link>http://seekingalpha.com/currents/post/1094162?source=feed</link>
        <guid isPermaLink="false">1094162</guid>
        <content>
          <![CDATA[ Sonoco Products ([[SON]] -1.4%) is downgraded to Neutral from Outperform with an amended price objective of $37 by Robert W. Baird, which says that while SON management is pursuing the right strategy of portfolio optimization and a bias toward share buybacks, YTD share outperformance has left the risk-reward ratio less compelling. <a href="http://seekingalpha.com/currents/post/1094162?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:59:16 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Sonoco Products (<a href='http://seekingalpha.com/symbol/son' title='Sonoco Products Co.'>SON</a> <font color="red">-1.4%</font>) is <a href="http://www.streetinsider.com/Downgrades/Baird+Downgrades+Sonoco+Products+%28SON%29+to+Neutral/8429893.html" target="_blank">downgraded</a> to Neutral from Outperform with an amended price objective of $37 by Robert W. Baird, which says that while SON management is pursuing the right strategy of portfolio optimization and a bias toward share buybacks, YTD share outperformance has left the risk-reward ratio less compelling. <a href="http://seekingalpha.com/currents/post/1094162?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Lunch service is a good thing if you're a restaurant, something BofA analyst Joseph Buckley reinforces Wednesday, upping his price target on Bloomin' Brands ([[BLMN]] +1.9%) to $29 from $25, citing a positive outlook for the introduction of lunch service at Outback locations. "Weekday lunch &hellip; is expected to be in 34% of Outback restaurants by YE 2013 and eventually in 50%-60% of the chain," Buckley notes.]]></title>
        <link>http://seekingalpha.com/currents/post/1094152?source=feed</link>
        <guid isPermaLink="false">1094152</guid>
        <content>
          <![CDATA[ Lunch service is a good thing if you're a restaurant, something BofA analyst Joseph Buckley reinforces Wednesday, upping his price target on Bloomin' Brands ([[BLMN]] +1.9%) to $29 from $25, citing a positive outlook for the introduction of lunch service at Outback locations. "Weekday lunch &hellip; is expected to be in 34% of Outback restaurants by YE 2013 and eventually in 50%-60% of the chain," Buckley notes. <a href="http://seekingalpha.com/currents/post/1094152?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:58:09 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Lunch service <a target="_blank" href="http://www.benzinga.com/analyst-ratings/analyst-color/13/06/3689657/update-bank-of-america-raises-po-on-bloomin-brands-as-ou">is a good thing</a> if you're a restaurant, something BofA analyst Joseph Buckley reinforces Wednesday, upping his price target on Bloomin' Brands (<a href='http://seekingalpha.com/symbol/blmn' title='Bloomin&#39; Brands'>BLMN</a> <font color="green">+1.9%</font>) to $29 from $25, citing a positive outlook for the introduction of lunch service at Outback locations. "Weekday lunch &hellip; is expected to be in 34% of Outback restaurants by YE 2013 and eventually in 50%-60% of the chain," Buckley notes. <a href="http://seekingalpha.com/currents/post/1094152?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Though a new Congressional bill proposes to legalize and regulate online gambling across the U.S., online gambling proponents remain skeptical the bill will end the industry's legal battle. Casinos, tribes, state lotteries, and other interest groups are still fighting for special rights, ideological opposition remains, and the bill features an opt-out provision for individual states and tribes. On the other hand, public support for legalization has been growing, and Nevada and New Jersey's moves have led other states to worry about being left out.  [[ZNGA]] and [[GLUU]] are both waiting for the chance to expand their online gambling efforts from the U.K. to the U.S. (I, II).]]></title>
        <link>http://seekingalpha.com/currents/post/1094142?source=feed</link>
        <guid isPermaLink="false">1094142</guid>
        <content>
          <![CDATA[ Though a new Congressional bill proposes to legalize and regulate online gambling across the U.S., online gambling proponents remain skeptical the bill will end the industry's legal battle. Casinos, tribes, state lotteries, and other interest groups are still fighting for special rights, ideological opposition remains, and the bill features an opt-out provision for individual states and tribes. On the other hand, public support for legalization has been growing, and Nevada and New Jersey's moves have led other states to worry about being left out.  [[ZNGA]] and [[GLUU]] are both waiting for the chance to expand their online gambling efforts from the U.K. to the U.S. (I, II). <a href="http://seekingalpha.com/currents/post/1094142?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:55:58 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Though a new <a href="http://thehill.com/blogs/floor-action/house/303935-rep-peter-king-introduces-online-gambling-bill#ixzz2WZokozCk" target="_blank">Congressional bill</a> proposes to legalize and regulate online gambling across the U.S., online gambling proponents <a href="http://www.theverge.com/2013/6/19/4444738/online-gambling-haters-mellow-out-but-federal-law-still-hung-up-on-special-interests" target="_blank">remain skeptical</a> the bill will end the industry's legal battle. Casinos, tribes, state lotteries, and other interest groups are still fighting for special rights, ideological opposition remains, and the bill features an opt-out provision for individual states and tribes. On the other hand, public support for legalization has been growing, and <a href="http://seekingalpha.com/currents/post/903971" target="_blank">Nevada</a> and <a href="http://seekingalpha.com/currents/post/853741" target="_blank">New Jersey's</a> moves have led other states to worry about being left out.&nbsp; <a href='http://seekingalpha.com/symbol/znga' title='Zynga'>ZNGA</a> and <a href='http://seekingalpha.com/symbol/gluu' title='Glu Mobile Inc.'>GLUU</a> are both waiting for the chance to expand their online gambling efforts from the U.K. to the U.S. (<a href="http://seekingalpha.com/currents/post/923201" target="_blank">I</a>, <a href="http://seekingalpha.com/currents/post/891821" target="_blank">II</a>). <a href="http://seekingalpha.com/currents/post/1094142?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Consolidated Graphics ([[CGX]] -0.5%) makes a move to expand in the Midwest by acquiring Universal Printing for an undisclosed sum. Universal Printing is a web and sheetfed commercial printing company based out of St. Louis, Missouri. The deal fits into [[CGX]]'s acquisition-related growth strategy, and a well-timed call by Stonegate Securities back in February. The stock has already risen over 30% since the firm made its bullish call with a $64 price target.]]></title>
        <link>http://seekingalpha.com/currents/post/1094132?source=feed</link>
        <guid isPermaLink="false">1094132</guid>
        <content>
          <![CDATA[ Consolidated Graphics ([[CGX]] -0.5%) makes a move to expand in the Midwest by acquiring Universal Printing for an undisclosed sum. Universal Printing is a web and sheetfed commercial printing company based out of St. Louis, Missouri. The deal fits into [[CGX]]'s acquisition-related growth strategy, and a well-timed call by Stonegate Securities back in February. The stock has already risen over 30% since the firm made its bullish call with a $64 price target. <a href="http://seekingalpha.com/currents/post/1094132?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:55:17 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Consolidated Graphics (<a href='http://seekingalpha.com/symbol/cgx' title='Consolidated Graphics, Inc.'>CGX</a> <font color="red">-0.5%</font>) makes a <a href="http://seekingalpha.com/news-article/6864952-consolidated-graphics-signs-letter-of-intent-to-acquire-universal-printing-company" target="_blank">move to expand</a> in the Midwest by acquiring Universal Printing for an undisclosed sum. Universal Printing is a web and sheetfed commercial printing company based out of St. Louis, Missouri. The deal fits into <a href='http://seekingalpha.com/symbol/cgx' title='Consolidated Graphics, Inc.'>CGX</a>'s acquisition-related growth strategy, and a <a href="http://seekingalpha.com/market_currents/post/813331" target="_blank">well-timed call</a> by Stonegate Securities back in February. The stock has already risen over 30% since the firm made its bullish call with a $64 price target. <a href="http://seekingalpha.com/currents/post/1094132?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Shares of Buffalo Wild Wings ([[BWLD]] +0.4%) cross into triple digits for the first time ever as investors continue to buy into the restaurant operator's growth potential. What to watch: The company's Q2 comparable-store sales and margins will be in focus to see the impact on results from an against-the-grain menu strategy to move to selling a quantity (small, medium, or large) of wings instead of letting consumers choose a specific number of wings.]]></title>
        <link>http://seekingalpha.com/currents/post/1094122?source=feed</link>
        <guid isPermaLink="false">1094122</guid>
        <content>
          <![CDATA[ Shares of Buffalo Wild Wings ([[BWLD]] +0.4%) cross into triple digits for the first time ever as investors continue to buy into the restaurant operator's growth potential. What to watch: The company's Q2 comparable-store sales and margins will be in focus to see the impact on results from an against-the-grain menu strategy to move to selling a quantity (small, medium, or large) of wings instead of letting consumers choose a specific number of wings. <a href="http://seekingalpha.com/currents/post/1094122?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:45:37 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Shares of Buffalo Wild Wings (<a href='http://seekingalpha.com/symbol/bwld' title='Buffalo Wild Wings, Inc.'>BWLD</a> <font color='green'>+0.4%</font>) cross into triple digits for the first time ever as investors continue to buy into the restaurant operator's growth potential. What to watch: The company's Q2 comparable-store sales and margins will be in focus to see the impact on results from an <a href="http://seekingalpha.com/currents/post/980881" target="_blank">against-the-grain menu strategy</a> to move to selling a quantity (small, medium, or large) of wings instead of letting consumers choose a specific number of wings. <a href="http://seekingalpha.com/currents/post/1094122?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Midday top 10 gainers: [[MNOV]] +28%. [[AVHI]] +18%. [[DGLY]] +18%. [[ARL]] +16%. [[TRUE]] +13%. [[AQQ]] +13%. [[DQ]] +13%. [[ASYS]] +12%. [[MFRI]] +12%. [[ICPT]] +11%. Midday top 10 Losers: [[OSH]] -63%. [[NRGY]] -38%. [[VNDA]] -24%. [[ZN]] -20%. [[FMAR]] -16%. [[TTEK]] -13%. [[VTSS]] -12%. [[CPGI]] -11%. [[VIPS]] -10%. [[BIOD]] -10%.]]></title>
        <link>http://seekingalpha.com/currents/post/1094112?source=feed</link>
        <guid isPermaLink="false">1094112</guid>
        <content>
          <![CDATA[ Midday top 10 gainers: [[MNOV]] +28%. [[AVHI]] +18%. [[DGLY]] +18%. [[ARL]] +16%. [[TRUE]] +13%. [[AQQ]] +13%. [[DQ]] +13%. [[ASYS]] +12%. [[MFRI]] +12%. [[ICPT]] +11%. Midday top 10 Losers: [[OSH]] -63%. [[NRGY]] -38%. [[VNDA]] -24%. [[ZN]] -20%. [[FMAR]] -16%. [[TTEK]] -13%. [[VTSS]] -12%. [[CPGI]] -11%. [[VIPS]] -10%. [[BIOD]] -10%. <a href="http://seekingalpha.com/currents/post/1094112?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:45:28 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ <b>Midday top 10 gainers:</b> <a href='http://seekingalpha.com/symbol/mnov' title='MediciNova, Inc.'>MNOV</a> <font color="green">+28%</font>. <a href='http://seekingalpha.com/symbol/avhi' title='AV Homes, Inc'>AVHI</a> <font color="green">+18%</font>. <a href='http://seekingalpha.com/symbol/dgly' title='Digital Ally, Inc.'>DGLY</a> <font color="green">+18%</font>. <a href='http://seekingalpha.com/symbol/arl' title='American Realty Investors, Inc.'>ARL</a> <font color="green">+16%</font>. TRUE <font color="green">+13%</font>. <a href='http://seekingalpha.com/symbol/aqq' title='American Spectrum Realty, Inc'>AQQ</a> <font color="green">+13%</font>. <a href='http://seekingalpha.com/symbol/dq' title='DAQO New Energy Corp.'>DQ</a> <font color="green">+13%</font>. <a href='http://seekingalpha.com/symbol/asys' title='Amtech Systems, Inc.'>ASYS</a> <font color="green">+12%</font>. <a href='http://seekingalpha.com/symbol/mfri' title='MFRI, Inc.'>MFRI</a> <font color="green">+12%</font>. <a href='http://seekingalpha.com/symbol/icpt' title='Intercept Pharmaceuticals'>ICPT</a> <font color="green">+11%</font>. <br /><b>Midday top 10 Losers:</b> <a href='http://seekingalpha.com/symbol/osh' title='Orchard Supply Hardware Stores Corporation'>OSH</a> <font color="red">-63%</font>. <a href='http://seekingalpha.com/symbol/nrgy' title='Inergy, L.P.'>NRGY</a> <font color="red">-38%</font>. <a href='http://seekingalpha.com/symbol/vnda' title='Vanda Pharmaceuticals Inc.'>VNDA</a> <font color="red">-24%</font>. <a href='http://seekingalpha.com/symbol/zn' title='Zion Oil & Gas Inc'>ZN</a> <font color="red">-20%</font>. FMAR <font color="red">-16%</font>. <a href='http://seekingalpha.com/symbol/ttek' title='Tetra Tech, Inc.'>TTEK</a> <font color="red">-13%</font>. <a href='http://seekingalpha.com/symbol/vtss' title='Vitesse Semiconductor Corp.'>VTSS</a> <font color="red">-12%</font>. <a href='http://seekingalpha.com/symbol/cpgi' title='China Shengda Packaging Group, Inc.'>CPGI</a> <font color="red">-11%</font>. <a href='http://seekingalpha.com/symbol/vips' title='Vipshop Holdings'>VIPS</a> <font color="red">-10%</font>. <a href='http://seekingalpha.com/symbol/biod' title='Biodel Inc.'>BIOD</a> <font color="red">-10%</font>. <a href="http://seekingalpha.com/currents/post/1094112?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
      <item>
        <title><![CDATA[Bank of Ireland ([[IRE]] +0.6%) is upgraded to Hold from Sell at Deutsche Bank, perhaps finding the price enticing after an 11% decline over the past few sessions (helped by a Goldman downgrade).]]></title>
        <link>http://seekingalpha.com/currents/post/1094102?source=feed</link>
        <guid isPermaLink="false">1094102</guid>
        <content>
          <![CDATA[ Bank of Ireland ([[IRE]] +0.6%) is upgraded to Hold from Sell at Deutsche Bank, perhaps finding the price enticing after an 11% decline over the past few sessions (helped by a Goldman downgrade). <a href="http://seekingalpha.com/currents/post/1094102?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]>
        </content>
        <pubDate>Wed, 19 Jun 2013 12:43:23 -0400</pubDate>
        <author>SeekingAlpha</author>
        <description><![CDATA[ Bank of Ireland (<a href='http://seekingalpha.com/symbol/ire' title='The Governor and Company of the Bank of Ireland'>IRE</a> <font color='green'>+0.6%</font>) is <a href="https://twitter.com/OwenCallan/status/347392641413021696" target="_blank">upgraded to Hold</a> from Sell at Deutsche Bank, perhaps finding the price enticing after an 11% decline over the past few sessions (helped by a <a href="http://seekingalpha.com/currents/post/1077132" target="_blank">Goldman downgrade</a>). <a href="http://seekingalpha.com/currents/post/1094102?source=feed"><img src="http://static.cdn-seekingalpha.com/images/universal/comment_icon2.gif" /> Post your comment!</a>]]></description>
      </item>
  </channel>
</rss>
